| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00134-005-2691-4 |
| P698 | PubMed publication ID | 15983759 |
| P2093 | author name string | Elisa Estenssoro | |
| Carlos Ramos | |||
| Gustavo Martins | |||
| Rosa Reina | |||
| Héctor S Canales | |||
| Andrea Das Neves | |||
| Gabriela Sáenz | |||
| Gabriela Vidal | |||
| Oscar Santander | |||
| Romina Gonzalvo | |||
| P2860 | cites work | Clinical Problems Posed by Multiresistant Nonfermenting Gram‐Negative Pathogens | Q54127739 |
| Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. | Q54146487 | ||
| National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System | Q56898992 | ||
| Acinetobacter baumannii: a threat for the ICU? | Q57238038 | ||
| RecurrentPseudomonas aeruginosaPneumonia in Ventilated Patients | Q57238109 | ||
| Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumannii | Q63197407 | ||
| Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients | Q69801500 | ||
| Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia | Q70530071 | ||
| Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group | Q71690220 | ||
| The safety and diagnostic accuracy of minibronchoalveolar lavage in patients with suspected ventilator-associated pneumonia | Q72157684 | ||
| Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia | Q73923634 | ||
| Outcome of long-stay intensive care patients | Q73997341 | ||
| The pharmacokinetics of colistin in patients with cystic fibrosis | Q74011059 | ||
| Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine | Q22306067 | ||
| Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients | Q24651466 | ||
| Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis | Q33489156 | ||
| Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria | Q33735389 | ||
| Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines | Q33970910 | ||
| In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak | Q33979213 | ||
| Computed Tomography of the Head before Lumbar Puncture in Adults with Suspected Meningitis | Q34104963 | ||
| Guidelines for the management of intravascular catheter-related infections | Q34219610 | ||
| Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy | Q34233910 | ||
| Neurotoxic and Nephrotoxic Effects of Colistin in Patients with Renal Disease | Q34254394 | ||
| Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. | Q34480866 | ||
| The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting | Q34509624 | ||
| The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection | Q34755628 | ||
| Infection in the chronically critically ill: unique risk profile in a newly defined population | Q34761329 | ||
| The standardization of bronchoscopic techniques for ventilator-associated pneumonia | Q35484329 | ||
| Treatment failures in patients with ventilator-associated pneumonia | Q35685622 | ||
| Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia | Q36856249 | ||
| Acute bacterial meningitis in adults. A review of 493 episodes | Q39411298 | ||
| In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. | Q39476552 | ||
| Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients | Q39487652 | ||
| Polymyxin B, Colistin, and Sodium Colistimethate | Q40128513 | ||
| Validation of different techniques for the diagnosis of ventilator-associated pneumonia. Comparison with immediate postmortem pulmonary biopsy | Q40704822 | ||
| Is the duration of mechanical ventilation predictable? | Q40881425 | ||
| The effect of late-onset ventilator-associated pneumonia in determining patient mortality | Q40965422 | ||
| Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial | Q42624106 | ||
| Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study | Q44043080 | ||
| Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. | Q44417867 | ||
| Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study | Q44609136 | ||
| Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System | Q44727502 | ||
| The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee | Q45265404 | ||
| Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. | Q47646856 | ||
| Shock on admission day is the best predictor of prolonged mechanical ventilation in the ICU. | Q47850122 | ||
| Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. | Q47968515 | ||
| A reassessment of the in-vitro activity of colistin sulphomethate sodium | Q50135598 | ||
| Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body | Q51120557 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1058-1065 | |
| P577 | publication date | 2005-06-28 | |
| P1433 | published in | Intensive Care Medicine | Q15749164 |
| P1476 | title | Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study | |
| P478 | volume | 31 |
| Q34074975 | A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa |
| Q43452961 | Acinetobacter baumannii infections in a surgical intensive care unit: predictors of multi-drug resistance |
| Q34795807 | Acinetobacter baumannii: emergence of a successful pathogen |
| Q42627289 | Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. |
| Q33732524 | Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections |
| Q42908865 | Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia |
| Q38414785 | Clinical efficacy and safety of colistin treatment in patients with pulmonary infection caused by Pseudomonas aeruginosa or Acinetobacter baumannii: a meta-analysis |
| Q38186636 | Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis |
| Q43179104 | Colistin administration to pediatric and neonatal patients |
| Q41871984 | Colistin and polymyxin B: a re-emergence |
| Q45974680 | Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. |
| Q24673399 | Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients |
| Q42204009 | Colistin nephrotoxicity increases with age. |
| Q53838114 | Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study. |
| Q40777387 | Colistin, an Old Drug in a New Territory, Solid Organ Transplantation |
| Q38514980 | Colistin: efficacy and safety in different populations. |
| Q37968280 | Colistin: new lessons on an old antibiotic |
| Q34560321 | Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections |
| Q38232199 | Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date |
| Q37330689 | Current control and treatment of multidrug-resistant Acinetobacter baumannii infections |
| Q37319452 | Defining, treating and preventing hospital acquired pneumonia: European perspective |
| Q37848401 | Effect of colistin on phospholipid-based activated partial thromboplastin time clotting assay results in patients receiving concomitant heparin therapy. |
| Q53250268 | Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria |
| Q45981762 | Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. |
| Q43124623 | Effectiveness and safety of colistin: prospective comparative cohort study |
| Q28539496 | Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: a systematic review and meta-analysis |
| Q49706174 | Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study |
| Q42658223 | Evaluating Adherence of Health-Care Team to Standard Guideline of Colistin Use at Intensive Care Units of a Referral Hospital in Shiraz, Southwest of Iran. |
| Q38961737 | Expert synthesis of the literature to support critical care decision making |
| Q36095081 | Global challenge of multidrug-resistant Acinetobacter baumannii |
| Q37869910 | Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. |
| Q35977417 | High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. |
| Q35457068 | How to treat VAP due to MDR pathogens in ICU patients |
| Q42277755 | Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality |
| Q42275806 | Impact of the initiation time of colistin treatment for Acinetobacter infections |
| Q37409893 | In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008. |
| Q37915360 | Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update. |
| Q46516945 | Intravenous colistimethate for multidrug-resistant Gram-negative bacteria |
| Q83390539 | Management of antimicrobial use in the intensive care unit |
| Q92302883 | Meta-analysis of Polymyxin Use in Patients |
| Q40845430 | Multidrug-resistant Acinetobacter baumannii infections in lung transplant patients in the cardiothoracic intensive care unit |
| Q35002302 | Multidrug-resistant Gram-negative infections: what are the treatment options? |
| Q43097126 | Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa |
| Q50990199 | Nephrotoxicity Associated with Intravenous Colistin in Critically Ill Patients |
| Q43290978 | Nephrotoxicity associated with the use of intravenous colistin |
| Q37636150 | New information about the polymyxin/colistin class of antibiotics |
| Q36894462 | Non-fermentative Gram-negative bacteria |
| Q36994518 | Nosocomial Acinetobacter pneumonia |
| Q38672016 | Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance |
| Q38416932 | Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia |
| Q33653353 | Parenteral colistin for the treatment of severe infections: a single center experience |
| Q37544285 | Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis |
| Q36960059 | Polymyxin B: similarities to and differences from colistin (polymyxin E). |
| Q37215935 | Polymyxins revisited |
| Q82669474 | Polymyxins: old antibiotics are back |
| Q36664072 | Post-neurosurgical meningitis due to multidrug-resistant Acinetobacter baumanii treated with intrathecal colistin: case report and review of the literature |
| Q43249112 | Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. |
| Q37058361 | Prognostic differences between VAP from Acinetobacter baumanii and VAP from other microorganisms |
| Q34165319 | Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia |
| Q27499294 | Renal and neurological side effects of colistin in critically ill patients |
| Q37009606 | Resurgence of colistin use. |
| Q35541277 | Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing |
| Q33416170 | Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections |
| Q80387733 | Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study |
| Q35218683 | Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study proto |
| Q38548658 | Strategies for the safe use of colistin |
| Q43983010 | Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin |
| Q40965515 | Task force on management and prevention of Acinetobacter baumannii infections in the ICU. |
| Q93117700 | The Utility of Colistin in Multiple Drug-Resistant Pseudomonas aeruginosa Bacterial Keratitis in a Kaposi’s Sarcoma Patient |
| Q37069191 | The current state of multidrug-resistant gram-negative bacilli in North America |
| Q42263402 | The impact of early adequate antimicrobial therapy on 14-day mortality in patients with monomicrobial Pseudomonas aeruginosa and Acinetobacter baumannii bacteremia |
| Q38586123 | The safety of polymyxin antibiotics |
| Q34652418 | The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature |
| Q92302910 | Toxicity in Patients |
| Q21092897 | Toxicity of polymyxins: a systematic review of the evidence from old and recent studies |
| Q37058001 | Treatment options for multidrug-resistant Acinetobacter species |
| Q36607401 | Treatment options for multidrug-resistant bacteria. |
| Q92302887 | Use of Colistin in Critically Ill Patients |
| Q41281850 | Variables determining the development of colistin-associated renal impairment |
| Q37907967 | When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock |
| Q36399486 | Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury |
Search more.